35 Drugs racing to treat new Coronavirus, But THIS one Looks Promising (COVID-19)

0

The world is scrambling to find a vaccine to treat the new coronavirus (COVID-19) as new cases keep emerging, a survey by Genetic Engineering & Biotechnology News (GEN) has revealed that 35 active drug development programmes are currently on in North America, Europe and China.

Big pharma companies like GlaxoSmithKline and Sanofi to small biotechs such as Moderna and Gilead Sciences are in the race but the researchers worldwide feel a vaccine to treat COVID-19 is at least 12 month away.

Gilead has already begun clinical trials in China after peer-reviewed journals showed that its antiviral candidate, remdesivir, had positive results in a case involving a US patient and Chinese in vitro tests.

Global bio-pharmaceutical company Takeda said this week it has initiated development of a plasma-derived therapy for new coronavirus (COVID-19) and produce the therapy termed as “TAK-888”.

Hyper immune globulins are plasma derived-therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections and may be a treatment option for COVID-19.

As a leader in plasma-derived therapies with more than 75 years of experience in the development of plasma-derived products, Takeda has the expertise to research, develop, and manufacture a potential therapy, referring to as “TAK-888,” the company said.

Researchers have also found a drug called camostat mesylate, that they believe may work to combat the novel coronavirus (COVID-19), which has claimed over 3,000 lives globally, majority of them in China, the virus’s country of origin.

WUHAN, Jan. 24, 2020 (Xinhua) — Peng Zhiyong (C), head of the department of critical care medicine of Zhongnan Hospital, performs diagnosis on a patient with his colleagues in Zhongnan Hospital of Wuhan University in Wuhan, central China’s Hubei Province, Jan. 24, 2020. Central China’s Hubei province reported 105 new confirmed cases of pneumonia caused by the novel coronavirus (2019-nCoV) and seven new deaths on Thursday, the provincial health authorities announced Friday. (Xinhua/Xiong Qi/IANS)
Bengaluru: People being distributed masks and offered sanitizer as part of an awareness drive urging people to take precautionary measures against Coronavirus, in Bengaluru on March 5, 2020. (Photo: IANS)
Chennai: People wear masks as a precautionary measure against the novel coronavirus outbreak; at Chennai International Airport on Feb 1, 2020. (Photo: IANS)
Coronavirus.
Medical staff wearing protective suits check documents as they wait for people with suspected symptoms of the new coronavirus, at a testing facility in Seoul, South Korea, Wednesday, March 4, 2020. The coronavirus epidemic shifted increasingly westward toward the Middle East, Europe and the United States on Tuesday, with governments taking emergency steps to ease shortages of masks and other supplies for front-line doctors and nurses. (AP Photo/Ahn Young-joon)
Filmmaker Tahira Kashyap is worried after seeing the increase in the number of people infected by coronavirus in India. She recently took to Instagram and posted a selfie in which she is seen wearing a mask.
Pedestrians wear protective masks as they walk in Toronto on Monday, January 27, 2020. Canada’s first presumptive case of the novel coronavirus has been officially confirmed, Ontario health officials said Monday as they announced the patient’s wife has also contracted the illness. THE CANADIAN PRESS/Frank Gunn
Now, coronavirus impacts demand for Corona Beer.

Camostat mesilate is a drug approved in Japan for use in pancreatic inflammation.

“We have tested SARS-CoV-2 isolated from a patient and found that camostat mesilate blocks entry of the virus into lung cells,” said the study’s lead author Markus Hoffmann.

According to the GEN survey, another example is Pirfenidone – an idiopathic pulmonary fibrosis drug marketed by Roche and its Genentech subsidiary as Esbriet.

The drug would be studied in patients with severe and critical COVID-19, under a planned randomized, open-label clinical trial that has been prospectively registered by Tongji Hospital of Tongji Medical College, part of Huazhong Science and Technology University.

The US National Institute of Health (NIH) has announced that it will run the first US clinical trial evaluating an experimental treatment for COVID-19, by assessing remdesivir in patients at the University of Nebraska Medical Center in Omaha, where some Americans with the disease are being cared for or are under quarantine.

Remdesivir showed “no adverse events” when administered to the first American confirmed to be infected with the new virus, in a case study published in The New England Journal of Medicine.

 

This drug is the most Promising

Researchers have found a drug called camostat mesylate, that they believe may work to combat the novel coronavirus (COVID-19), which has claimed over 3,000 lives globally, majority of them in China, the virus’s country of origin.

Camostat mesilate is a drug approved in Japan for use in pancreatic inflammation.

According to the researchers, the new virus has been named SARS coronavirus-2 or (SARS-CoV-2) and has been transmitted from animals to humans. It causes a respiratory disease called COVID-19 that may take a severe course.

“We have tested SARS-CoV-2 isolated from a patient and found that camostat mesilate blocks entry of the virus into lung cells,” said the study’s lead author Markus Hoffmann.

For the findings, published in the journal cell, the research team led by infection biologists from the German Primate Centre wanted to find out how the new coronavirus enters host cells and how this process can be blocked.

They identified a cellular protein that is important for the entry of COVID-19 into lung cells.

“Our results show that SARS-CoV-2 requires the protease TMPRSS2, which is present in the human body, to enter cells, this protease is a potential target for therapeutic intervention,” said said study researcher Stefan Pohlmann from the German Primate Centre.

No vaccines or drugs are currently available to combat these viruses, the researchers said.

Since it is known that the drug camostat mesilate inhibits the protease TMPRSS2, the researchers have investigated whether it can also prevent infection with SARS-CoV-2.

“Our results suggest that camostat mesilate might also protect against COVID-19, this should be investigated in clinical trials,” Hoffmann added.

The coronavirus death toll in mainland China on Friday increased to 3,042 with an overall 80,552 infections and the number of global cases surpassed 95,000 with more than 3,000 fatalities.

According to the study, a team of scientists led from the German Primate Centre and including researchers from Charite, the University of Veterinary Medicine Hannover Foundation, the BG-Unfallklinik Murnau, the LMU Munich, the Robert Koch Institute and the German Center for Infection Research took part in the research.